Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306395 | 1.00 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL472213 | 1.00 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL27229072 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL5550813 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL5239633 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| Hydrochloric Acid SCHEMBL28968883 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL8038178 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL6537424 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL10567168 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL337070 | 0.98 | HSD17B10 (0.52) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | CHRM5 2123/4885CHRM3 1728/4885HSD17B10 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.